$ARWR News

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower Triglyceride Levels In Adult Patients With Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Leerink Partners Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $72

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Presents Interim Results From Phase 1/2a Clinical Trial Of ARO-INHBE, Investigational RNAi Therapeutic Developed As Potential Treatment For Obesity And Metabolic Dysfunction-Associated Steatohepatitis

Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Bernstein Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $46

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum